Riskpilot← Back to searchSign inGet full accessGynmater ObGyn AB
ABIn liquidationOrg 5592469810ÖsthammarMedical specialists activities · NACE 8622Est. 20201 employees
Revenue 2024
SEK 0
EBITDA margin
—
-112% vs 2023
Equity ratio
74.1%
Financial strength
Net profit 2024
SEK -30K
-112% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -30K | -112% |
| Net profit | SEK -30K | -112% |
| Total assets | SEK 80K | -79% |
| Equity | SEK 59K | -80% |
| Employees | 1 | — |
Legal name
Gynmater ObGyn AB
Org number
5592469810
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
10 mars 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Läkartjänster med behandlingsuppdrag inom primärvård och specialistmottagningar företrädesvis inom förlossningsverksamhet och därmed liknande verksamhet.
Address
Östhammar
Email
lars.gerne@nalgab.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 324 | 371 | 33 | 261 | 0 |
| Staff expenses | — | — | −250 | −0 | — |
| EBITDA | 304 | 12 | −226 | 248 | −30 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 304 | 12 | −226 | 248 | −30 |
| Net financials | — | — | −1 | 1 | 0 |
| Profit before tax | 229 | 87 | −227 | 248 | −30 |
| Tax | −49 | −19 | — | −5 | — |
| Net profit | 180 | 68 | −227 | 244 | −30 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 405 | 452 | 74 | 374 | 80 |
| Equity | 205 | 273 | 46 | 289 | 59 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 125 | 180 | 29 | 84 | 21 |
| Total debt | 125 | 180 | 29 | 84 | 21 |
EBITDA margin
-3029200.0%
This company
15.8%
Market median
-19172252% vs market
20202024
Equity ratio
74.1%
This company
38.2%
Market median
+94% vs market
20202024
Return on equity
-50.9%
This company
18.4%
Market median
-377% vs market
20202024
Net profit margin
-3012900.0%
This company
8.1%
Market median
-37196396% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-03-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LH Liquidator | Liquidator | 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2020 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gynmater ObGyn AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Harald Gerne | Liquidator | 0 companies |
| Dan Richard Johansson | Board of Directors | 0 companies |
| Paula Da Silva Charvalho | Board of Directors | 0 companies |